Compared with IDH-wildtype glioblastoma patients with GC, IDH-mutant patients with GC were significantly younger, had a greater proportion of females, less frequent contrast enhancement, a lower proportion of contrast-enhancing tumors (> 5%), less necrosis, less diffusion restriction, less hemorrhage, less frequent manifestation of GC type 2, and a greater proportion of cystic changes. This evidence concerns the gene IDH1 and glioblastoma.